Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies

We investigated the administration of intravenous (i.v.) busulfan (Bu) combined with melphalan (Mel) in patients with advanced lymphoid malignancies undergoing autologous SCT. Bu 130 mg/m(2) was infused daily for 4 days, either as a fixed dose per BSA, or to target an average daily AUC of 5,000 uMol...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Kebriaei, P, Madden, T, Kazerooni, R, Wang, X, Thall, P, Ledesma, C, Nieto, Y, shpall, EJ, Hosing, C, Qazilbash, M, Popat, U, Khouri, I, Champlin, RE, Jones, RB, Andersson, BS
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4031688/
https://ncbi.nlm.nih.gov/pubmed/20674757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2010.07.016
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi